1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
Cholesterol-Lowering Drugs Market Forecast 2015-2025: Opportunities in PCSK9 Inhibitors, CETP Inhibitors, MTTP Inhibitors, ApoB Inhibitors and PPAR Agonists

Cholesterol-Lowering Drugs Market Forecast 2015-2025: Opportunities in PCSK9 Inhibitors, CETP Inhibitors, MTTP Inhibitors, ApoB Inhibitors and PPAR Agonists

  • November 2015
  • 199 pages
  • ID: 3516952

Summary

Table of Contents

Please note: The license is valid for 12 months from the date the report is sent.


Cholesterol-Lowering Drugs Market Forecast 2015-2025: Opportunities in PCSK9 Inhibitors, CETP Inhibitors, MTTP Inhibitors, ApoB Inhibitors and PPAR Agonists

What can be expected from the cholesterol-lowering drugs market? Which areas are going to grow at the fastest rates? This visiongain report shows you potential revenues to 2025, assessing data, trends, opportunities and prospects there.


Our 199-page report provides 153 tables, charts, and graphs. Discover the most lucrative areas in the industry and the future market prospects. Our new study lets you assess forecasted sales at overall world market and regional level. You will see financial results, an interview, trends, opportunities, and revenue predictions. There is much opportunity in this fast moving market.



Forecasts from 2015-2025 and other analyses show you commercial prospects



Besides revenue forecasting to 2025, our new study provides you with recent results, growth rates, and market shares. Discover qualitative analyses (including SWOT and Porter’s Five Forces analysis) and commercial developments.



See revenue forecasts for the leading submarkets and indications



How will submarkets perform to 2025? Our study forecasts revenues in the following cholesterol-lowering drugs submarkets and products:

- Statins and Fixed-Dose Combinations

o Crestor

o Lipitor

o Livalo

o Lescol/Lescol XL

o Zocor

o Vytorin

o Caduet

o Other Statins and Fixed-Dose Combinations (grouped forecast)

- Absorption Inhibitors, Ion Exchange Resins, Fibrates and Other Drugs

o Zetia

o Welchol

o Tricor

o Other cholesterol-lowering drugs (grouped forecast)

- PCSK9 Inhibitors

o Praluent

o Repatha

o RN316

o Other PCSK9 Inhibitors (grouped forecast)

- Novel Cholesterol-Lowering Drugs

o Juxtapid

o Kynamro

o MK-0859

o Other novel cholesterol-lowering drugs (grouped forecast)



See revenue forecasts for the leading international markets



How will leading national markets perform to 2025? Our study forecasts revenues in national markets including products, including:

- US

- Japan

- Germany

- France

- Italy

- Spain

- UK

- China

- Brazil

- Russia

- India



Leading companies and potential for market growth



Overall revenue for the cholesterol-lowering drugs market will reach $24.63bn in 2019, our work forecasts. We predict strong revenue growth through to 2025. Shifts in diets and lifestyles will contribute to rising levels of high cholesterol, while highly disruptive new treatments will revitalise the market



Our work analyses the key companies in the market. See visiongain’s analysis of 9 leading companies, including these:

- AstraZeneca

- Merck

- Pfizer

- Kowa

- Daiichi Sankyo

- Abbvie

- Novartis

- Sanofi

- Amgen


A company profile gives you the following information where available:

- Discussion of a company’s activities and outlook

- Analysis of products currently on the market as well as pipeline products

- Company news relevant to the market



Discover capabilities, progress, and commercial prospects, helping you stay ahead.



What issues will affect Cholesterol-Lowering Drugs industry?

Our new report discusses issues and events affecting the cholesterol-lowering drugs market. You will find discussions, including qualitative analyses:

- Highly disruptive treatments entering the market

- Increasing potential in both established and emerging markets



You will see discussions of technological, commercial, and economic matters, with emphasis on the competitive landscape and business outlooks.



How the Cholesterol-Lowering Drugs Market Forecast 2015-2025 report helps you


In summary, our 199-page report gives you the following knowledge:



- Revenue forecasts to 2025 for the Cholesterol-Lowering Drugs market – discover the industry’s prospects, finding promising places for investments and revenues

- Revenue forecasts to 2025 for submarkets in each – statins and fixed-dose combinations, absorption inhibitors, ion-exchange resins fibrates, PCSK9 inhibitors and novel drugs

- Revenue forecasts to 2025 for the leading regional markets – US, Japan, EU5 and BRIC

- Assessment of 9 leading companies – analysis of cholesterol-lowering products, revenue, news and upcoming product releases

- Discussion of what stimulates and restrains companies and the market

- Prospects for established firms and those seeking to enter the market

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 60 Million searchable statistics with tables, figures & datasets
  • More than 25,000 trusted sources
  • Single User License — provides access to the report by one individual.
  • Department License — allows you to share the report with up to 5 users
  • Site License — allows the report to be shared amongst all employees in a defined country
  • Corporate License — allows for complete access, globally.
Ahmad helps you find the right report:
Testimonials

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

We were impressed with the support that ReportLinker’s research specialists’ team provided. The report we purchased was useful and provided exactly what we want.

Category Manager at
Ikea

ReportLinker gave access to reliable and useful data while avoiding dispersing resources and spending too much time on unnecessary research.

Executive Director at
PwC Advisory

The customer service was fast, responsive, and 100% professional in all my dealings (...) If we have more research needs, I'll certainly prioritize working with ReportLinker!

Scott Griffith

Vice President Marketing at
Maurice Sporting Goods

The research specialist provided prompt, helpful instructions for accessing ReportLinker's product. He also followed up to make sure everything went smoothly and to ensure an easy transition to the next stage of my research

Jessica P Huffman

Research Associate at
American Transportation Research Institute

Excellent customer service. Very responsive and fast.

Director, Corporate Strategy at
Ingredion

I reached out to ReportLinker for a detailed market study on the Air Treatment industry. The quality of the report, the research specialist’s willingness to solve my queries exceeded my expectations. I would definitely recommend ReportLinker for in-depth industry information.

Mariana Mendoza

Global Platform Senior Manager at
Whirlpool Corporation

Thanks! I like what you've provided and will certainly come back if I need to do further research works.

Bee Hin Png

CEO at
LDR Pte Ltd

The research specialist advised us on the best content for our needs and provided a great report and follow-up, thanks very much we shall look at ReportLinker in the future.

Kate Merrick

Global Marketing Manager at
Eurotherm by Schneider Electric

FAQ
  • How we can help
    • I am not sure if the report I am interested in will fulfill my needs. Can you help me?
    • Yes, of course. You can call us at +33(0) 4 37 65 17 03 or drop us an email at researchadvisor@reportlinker.com to let us know more about your requirements.
    • We buy reports often - can ReportLinker get me any benefits?
    • Yes. Set up a call with a Senior Research Advisor to learn more - researchadvisor@reportlinker.com or +33(0) 4 37 65 17 03.
    • I have had negative experiences with market research reports before. How can you avoid this from happening again?
    • We advise all clients to read the TOC and Summary and list your questions so that we can get more insight for you before you make any purchase decision. A research advisor will accompany you so that you can compare samples and reports from different sources, and choose the study that is right for you.

  • Report Delivery
    • How and when I will receive my Report?
    • Most reports are delivered right away in a pdf format, while others are accessed via a secure link and access codes. Do note that sometimes reports are sent within a 12 hour period, depending on the time zones. However, you can contact us to escalate this. Should you need a hard copy, you can check if this option is offered for the particular report, and pay the related fees.
  • Payment conditions
    • What payment methods do you accept?
      1. Credit card : VISA, American Express, Mastercard, or
      2. You can download an invoice to pay by wire transfer, check, or via a Purchase Order from your company, or
      3. You can pay via a Check made out in US Dollars, Euros, or British Pounds for the full amount made payable to ReportLinker
    • What are ReportLinker’s Payment Terms?
    • All payments must normally be submitted within 30 days. However, you can let us know if you need extended time.
    • Are Taxes and duties included?
    • All companies based in France must pay a 20% tax per report. The same applies to all individuals based in the EU. All EU companies must supply their VAT number when purchasing to avoid this charge.
    • I’m not satisfied. Can I be refunded?
    • No. Once your order has been processed and the publisher has received a notification to send you the report, we cannot issue any refund or cancel any order. As these are not ‘traditional’ products that can be returned, reports that are dispatched are considered to be ‘consumed’.
  • User license
    • The license that you should acquire depends on the number of persons that need to access the report. This can range from Single User (only one person will have the right to read or access the report), or Department License (up to 5 persons), to Site License (a group of persons based in the same company location), or Corporate License (the entire company personnel based worldwide). However, as publishers have different terms and conditions, we can look into this for you.
Purchase Reports From Reputable Market Research Publishers
Heterozygous familial hypercholesterolemia (heFH) Global Clinical Trials Review, H2, 2017

Clinical Research in Heterozygous familial hypercholesterolemia (heFH) in H2, 2017

  • $ 2500
  • Industry report
  • September 2017
  • by GlobalData

Heterozygous familial hypercholesterolemia (heFH) Global Clinical Trials Review, H2, 2017SummaryGlobalData’s clinical trial report, “Heterozygous familial hypercholesterolemia (heFH) Global Clinical ...

Hypertriglyceridemia Global Clinical Trials Review, H2, 2017

Clinical Research in Hypertriglyceridemia in H2, 2017

  • $ 2500
  • Industry report
  • October 2017
  • by GlobalData

Hypertriglyceridemia Global Clinical Trials Review, H2, 2017SummaryGlobalData’s clinical trial report, “Hypertriglyceridemia Global Clinical Trials Review, H2, 2017" provides an overview of Hypertriglyceridemia ...

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor -Pipeline Insights, 2017

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor -Pipeline Insights, 2017

  • $ 1250
  • Industry report
  • November 2017
  • by Delve Insight

DelveInsight’s, “Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitor-Mechanism of action Insights, 2017”, report provides comprehensive insights of the ongoing therapeutic research and ...


ref:plp2015

Reportlinker.com © Copyright 2018. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.